Literature DB >> 8118819

Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

J M Birch1, A L Hartley, K J Tricker, J Prosser, A Condie, A M Kelsey, M Harris, P H Jones, A Binchy, D Crowther.   

Abstract

The entire coding sequence of the p53 gene was analysed for the presence of mutations in 12 families conforming to a restricted definition of Li-Fraumeni syndrome (classic LFS) and nine families with features of LFS conforming to a broader definition. Mutations were detected in seven families. Six were point mutations with one each affecting codons 175, 180, and 220 and three affecting codon 248. The seventh was a deletion/insertion mutation in exon 4. Germline mutations in p53 were a feature of families which included children with rhabdomyosarcoma and/or adrenal cortical carcinoma. Germline p53 mutations were detected in six of the nine families with such tumors. An analysis of these 7 mutations, together with 34 published examples, showed that more than one-half were transitions at CpG dinucleotides, suggesting that the majority of germline p53 mutations may arise as a result of spontaneous events. The most common cancers occurring in the 41 families with germline p53 mutations, in common with classic LFS, were bone and soft tissue sarcoma, breast cancer, brain tumors, leukemia, and adrenocortical carcinoma, although less than one-half of the probands with germline p53 mutations came from classic LFS families. More than one-half of the cancers overall and nearly one-third of the breast cancers were diagnosed before 30 years of age. These observations have important implications for asymptomatic carriers of germline p53 mutations, and there is a need for international collaboration in the development of protocols for the management of such families.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118819

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  152 in total

1.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Authors:  Judy Mouchawar; Christopher Korch; Tim Byers; Todd M Pitts; Efang Li; Margaret R E McCredie; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; P Arlauskas; W Du; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-06

3.  Familial gastric cancer: update for practice management.

Authors:  Giovanni Corso; Daniele Marrelli; Franco Roviello
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.

Authors:  Muhammad U Rashid; Sidra Gull; Kashif Asghar; Noor Muhammad; Asim Amin; Ute Hamann
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 5.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

6.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

7.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

Review 8.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

9.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.